Condition
Stage IIC Colon Cancer AJCC v8
Total Trials
3
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Active Not Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03516942Active Not Recruiting
Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
NCT05710406Phase 2Active Not Recruiting
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
NCT07140679Phase 2Recruiting
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Showing all 3 trials